ライフサイエンスコーパス: marrow graft

1 the presence of mature donor T cells in the marrow graft.

2 allogeneic, xenogeneic and missing self bone-marrow grafts.

3 y, on immune functions in six dogs not given marrow grafts.

4 1 Gy TBI and dog leukocyte antigen-identical marrow grafts.

5 so failed to inhibit rejection of TNFR1(-/-) marrow grafts.

6 DS/AML (RR = 1.8; P =.12) compared with bone marrow grafts.

7 ted mice receiving fully MHC-mismatched bone marrow grafts.

8 ntain about 10 times more T and B cells than marrow grafts.

9 T cells in unmanipulated PBSCs than in bone marrow grafts.

10 recipients transplanted with MHC-mismatched marrow grafts.

11 y irradiation and DLA-nonidentical unrelated marrow grafts.

12 major histocompatibility complex-mismatched marrow grafts.

13 eceiving blood transfusions or organ or bone marrow grafts.

14 reconstitution in recipients of MHC-matched marrow grafts.

15 osphamide, then were transplanted with CD34+ marrow grafts.

16 nd mismatched (B10.BR[H-2k] --> DBA/2[H-2d]) marrow grafts.

17 eparations disqualified the use of the CD34+ marrow grafts.

18 the specific antitumor effect of allogeneic marrow grafts.

19 n 72 patients surviving 20 to 30 years after marrow grafting.

20 ompared with recipients of matched unrelated marrow grafts (23%).

21 The CD34+ marrow grafts administered to these patients contained a

22 In this model most animals rejected their marrow grafts after a preparative regimen of 9.2 Gy tota

23 Sixteen patients in group 3 received marrow grafts after failure to respond to immunosuppress

24 e fail to reject fully mismatched allogeneic marrow grafts and show enhanced survival after such tran

25 es (except pelvis), DLA-identical littermate marrow grafts, and MMF/CSP posttransplant.

26 100 cGy TBI, dog leukocyte antigen-identical marrow grafts, and mycophenolate mofetil/cyclosporine.

27 odel of hybrid resistance, in which parental marrow grafts are rejected solely by the NK cells of irr

28 randomized to receive an autologous CD34(+) marrow graft (Arm A) versus a standard buffy coat fracti

29 el, gzm B -/- hosts rejected haplo-identical marrow grafts as efficiently as did their wild-type litt

30 imary host barrier cells that recognize bone marrow grafts bearing hematopoietic histocompatibility a

31 row was abrogated by T-cell depletion of the marrow graft before infusion.

32 tein-Barr virus (EBV) lymphomas complicating marrow grafts, but they contain alloreactive T cells cap

33 l-mediated rejection of allogeneic H-2d bone marrow grafts by irradiated mice.

34 udies, we added mature donor T cells to bone marrow grafts combined with heart grafts, and compared m

35 T-lymphocyte depletion of bone marrow grafts compromises engraftment, suggesting a faci

36 facilitating engraftment, to T-cell depleted marrow grafts containing 160 x 10(6) activated gamma del

37 in allogeneic recipients of T-cell-depleted marrow grafts, exceeding the survival benefit of donor l

38 s of alpha beta T cells were required in the marrow graft for the eradication of residual host T cell

39 e (<40 v >/=40) and for male recipients of a marrow graft from an alloimmunized female.

40 conditioning, simultaneous administration of marrow grafts from 2 DLA-identical littermates could res

41 All patients received bone marrow grafts from an unrelated donor and a myeloablativ

42 35 days resulted in establishment of stable marrow grafts from DLA-identical canine littermates afte

43 ti-CD45 or anti-TCRalphabeta mAb followed by marrow grafts from DLA-identical littermates and postgra

44 Accordingly, 12 dogs were given 9.2 Gy TBI, marrow grafts from DLA-mismatched unrelated dogs, and a

45 total-body irradiation (TBI) and unmodified marrow grafts from dog leukocyte antigen (DLA)-identical

46 Previous studies have demonstrated that most marrow grafts from dog leukocyte antigen (DLA)-mismatche

47 s with hematologic malignancies who received marrow grafts from either phenotypically matched unrelat

48 and 58 mismatched) and 48 patients received marrow grafts from family donors that were mismatched at

49 essed in 17 patients who received allogeneic marrow grafts from HLA-matched siblings between 1971 and

50 PBPCs and bone-marrow grafts from unrelated adult donors were matched f

51 smatched at a single HLA locus received bone marrow grafts from unrelated donors.

52 se, 0.1-5.9 mCi/kg [3.7-218 MBq/kg]) without marrow grafts had no toxic effects other than a mild, re

53 T-cell depletion (TCD) of the donor marrow graft has been shown to reduce the severity of gr

54 e that recipients of both unmodified and TCD marrow grafts have profound deficiencies of EBV-specific

55 st-generation back-crossed mice rejected H2b marrow grafts (hybrid resistance), transgene-positive mi

56 R] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43;

57 Ralphabeta prevented rejection of allogeneic marrow grafts in the setting of conditioning with a rela

58 pregnancy and healthy childbirth after bone marrow grafting is relatively rare due to irradiation, b

59 CML patients initially transplanted with TCD marrow grafts is not defined.

60 Alloreactive donor T cells in marrow grafts mediate graft-versus-host disease (GVHD),

61 eks after transplantation, and hCD34(+) bone marrow grafts of primary recipients could reconstitute h

62 CR T cells in arrbetagal mice by use of bone marrow grafts, or double-transgenic mice, also gave no r

63 ipient CD8 effectors responsible for causing marrow graft rejection are sensitive to cytotoxicity med

64 The present study examined models where marrow graft rejection can be prevented by donor T cells

65 To evaluate whether the ability to prevent marrow graft rejection could be dissociated from the abi

66 r CD4 cells are not essential for preventing marrow graft rejection in humans.

67 r eliminating recipient CD8 cells that cause marrow graft rejection in mice.

68 In conclusion, T cell-mediated marrow graft rejection primarily resembles a Th1-type pr

69 In two distinct marrow graft rejection systems, host CD8(+) and CD4(+) T

70 d enable donor T cells to prevent allogeneic marrow graft rejection without causing GVHD.

71 We conclude that Tc2 cells potently inhibit marrow graft rejection without inducing an alloaggressiv

72 + T cells capable of host reactivity inhibit marrow graft rejection, but also generate graft-versus-h

73 LA-A or HLA-B antigens increases the risk of marrow graft rejection, but the relevance of HLA-C is un

74 se T cells and NK cells are critical in bone marrow graft rejection, our purpose was to examine wheth

75 play a pivotal role in preventing allogeneic marrow graft rejection, possibly by generating cytotoxic

76 not activate NK cells) fails to enhance bone marrow graft rejection.

77 othesis that donor CD8 cells help to prevent marrow graft rejection.

78 al cytotoxic mechanism to prevent allogeneic marrow graft rejection.

79 it has been proposed that the cytotoxic bone marrow graft rejection.

80 lay a critical role in preventing allogeneic marrow graft rejection.

81 der versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL

82 feration) in host spleens was the measure of marrow graft success.

83 e (GVHD) was lower with T-cell-depleted bone marrow grafts; T-cell-depleted grafts were not associate

84 er, these data support the results from bone marrow grafts that circulating CD11b+ cells can enter th

85 naive gamma delta T cells to T-cell depleted marrow grafts was required to significantly increase all

86 n one log more T lymphocytes than unmodified marrow grafts, we evaluated the incidence of chronic GVH

87 Blood and bone marrow grafts were administered to 28 and three patients

88 T cell depletion of the marrow graft, which is currently used to prevent GVHD, h

89 he exception of recipients of haploidentical marrow grafts, who received antithymocyte globulin after

90 owed by a second TBI and RLI, rejected their marrow graft without rejecting their transplanted kidney

91 f CD4 cells from an HLA-mismatched unrelated marrow graft would substantially reduce the risk of grad